Venous Thromboembolism

NEW ORLEANS — Patients with cancer and COVID-19 exhibited a 3% risk for thromboembolism within 30 days of their first positive test, according to study results presented at ASH Annual Meeting and Exposition.

PHILADELPHIA — Opioid use in rheumatoid arthritis demonstrates a nearly two-fold increased risk for venous thromboembolism vs. NSAIDs, according to data presented at ACR Convergence 2022.

PHILADELPHIA — There is “no clear increased risk” for major adverse cardiovascular events associated with tofacitinib, according to a post-hoc analysis of the ORAL Surveillance trial presented at ACR Convergence 2022.

CHICAGO — In hospitalized medically ill patients, an electronic health record-based decision support system reduced major thromboembolic events compared with usual care, researchers reported.

Thromboembolism incidence appeared high among patients who received immunotherapy-based combinations for metastatic renal cell carcinoma, according to retrospective study results.

NASHVILLE, Tenn. — In this Healio exclusive, Samantha Pettigrew, MD, discusses CHEST’s 2021 update to its clinical guidelines on using anticoagulation for venous thromboembolism at the CHEST Annual Meeting.

Compared with uninfected controls, patients hospitalized for COVID-19 had elevated risk for death and CV events, according to new data from the UK Biobank.

Patients with atopic dermatitis who are on Janus kinase inhibitors did not show an increased risk for venous thromboembolism, according to a study.

The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.

Combined oral contraceptives were associated with an increased risk for thrombotic events in women with obesity, according to a recent review.